FibroGen Inc. Releases Proforma Financials Following $220 Million Sale of FibroGen China to AstraZeneca
Reuters
Sep 06, 2025
FibroGen Inc. Releases Proforma Financials Following $220 Million Sale of FibroGen China to AstraZeneca
FibroGen Inc. has released its unaudited pro forma condensed consolidated financial statements in connection with its recent transaction involving the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. The transaction, valued at approximately $220 million, includes $85 million in enterprise value and about $135 million in net cash held in China. The financial statements, prepared in accordance with Article 11 of Regulation S-X, illustrate the impact of this transaction on FibroGen's historical financials. At the closing, FibroGen also repaid its $81 million senior secured term loan with Morgan Stanley Tactical Value and entered into a transition services agreement, among other customary agreements. The pro forma statements provide insights into the financial adjustments and anticipated outcomes of this significant M&A activity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000921299-25-000007), on September 05, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.